Moderna 2022 Priorities and Capital Allocation

Moderna's 2022 priorities 1 Execute on $21B signed APAs and prepare for Fall booster 2 3 4 Execute on four Phase 3 vaccine programs, which could lead to three respiratory commercial launches over the next two to three years Advance therapeutic programs and share proof-of-concept readouts for our PA, MMA and PCV programs Bring forward more mRNA candidates into development 5 Expand our mRNA platform Slide 37 moderna

View entire presentation